Factor Xa Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4.4
$ 6600
$ 8900

Factor X is the zymogen of a serine protease. Factor X, also known by the eponym Stuart–Prower factor, is an enzyme of the coagulation cascade. It is a serine endopeptidase. Factor X is synthesized in the liver and requires vitamin K for its synthesis. Factor X is activated by hydrolysis into factor Xa by both factor IX and factor VII with its cofactor, tissue factor. It is therefore the first member of the final common pathway or thrombin pathway. Factor Xa is generated by both the extrinsic and intrinsic coagulation pathways and is responsible for activating prothrombin to thrombin. Mechansism of action (MOA) of Factor Xa Inhibitor is that work by selectively and reversibly blocking the activity of clotting factor Xa, preventing clot formation. They affect both factor Xa within the blood and within a preexisting clot and do not affect platelet aggregation. Factor Xa Inhibitor for the treatment and prevention of deep vein thrombosis, acute pulmonary embolism, to reduce the risk of stroke and embolism in people with nonvalvular atrial fibrillation, reperfusion injury, acute coronary syndrome, heart diseases, kidney diseases, etc. Increased prevalence of cardiovascular disorders and changing lifestyle are the key drivers for the Factor Xa Inhibitor market. For instance, According to the Centers for Disease Control And Prevention 2021, every year, about 805,000 people in the United States have a heart attack. Launch of newer products by the market players could seek opportunities that influence extensive research and development in the Factor Xa Inhibitor market. For instance, Daiichi Sankyo Savaysa (Edoxaban) is used to treat venous thromboembolism, and atrial fibrillation. Moreover, the development of novel molecules by many market player are coming up to overcome challenges in therapy. For instance, Pfizer’s Marstacimab (PF-06741086)  for the treatment to prevent or reduce the frequency of bleeding episodes in individuals with severe hemophilia A are under the various stages of clinical studies.

Factor Xa Inhibitor Market Key Developments:

  • In May 2018, Portola Pharmaceuticals received FDA approval for Andexxa (Coagulation Factor Xa (Recombinant), Inactivated-Zhzo) for the treatment of reversal of factor Xa inhibitors.
  • In April 2021, Aspen Pharma (Nadroparin) has found that high therapeutic nadroparin dosages in preterm and term neonates seem to be safe with Venous Thromboembolism.

Approved Drug Molecules and Brand Names for Factor Xa Inhibitor:

  • Savaysa (Edoxaban)
  • Innohep (Tinzaparin)
  • Fraxiparine (Nadroparin)
  • Hibor (Bemiparin)
  • Andexxa (Coagulation Factor Xa (Recombinant), Inactivated -Zhzo)
  • Bevyxxa (Betrixaban)
  • Orgaran (Danaparoid)

Drugs under the Pipeline for Factor Xa Inhibitor:

  • Darexaban Maleate (YM150)
  • Ciraparantag (Aripazine)
  • Sandoparin (Certoparin Sodium)
  • Idraparinux Sodium (SANORG 34006)
  • Otamixaban (XRP0673)
  • Inhixa (Enoxaparin Biosimilar)
  • Dimolegin (Dioxaban)
  • Ckd-344
  • Gcc-4401c
  • Syha136

Clinical Activity and Developments of Factor Xa Inhibitor:

Till June 2023, more than 15 companies having approximately 21 molecules targetting the number of cardiovascualr diseases. For these molecules, more than 347 clinical trials are being conducted and majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,

  • In February 2023, AstraZeneca’s Bevyxxa (Betrixaban) has completed phase 3, a multicenter, randomized, active-controlled study for evaluating the safety and efficacy for the prevention of venous thromboembolism in acute ill patients.
  • In February 2021, Merck’s Danaparoid completed phase 1, double blind, randomised, single centre, parallel group study for evaluating the safety and tolerability of Danaparoid (DNDI-0690) in healthy subjects for cutaneous leishmaniasis.

Molecule Name

Number of Studies

Darexaban Maleate (YM150)


Ciraparantag (Aripazine)


Sandoparin (Certoparin Sodium)


Idraparinux Sodium (SANORG 34006)


Otamixaban (XRP0673)


Target Indication Analysis of Factor Xa Inhibitor

The molecules such as Savaysa (Edoxaban) developed by Daiichi Sankyo for the treatment of blood clots and strokes. LEO Pharma’s Innohep (Tinzaparin) is used to treat serious blood clots, usually in the legs. Aspen Pharma’s Fraxiparine (Nadroparin) used to prevent the blood from clotting after having surgery, during haemodialysis, during hospitalisation for acute illness or in intensive care unit with extended bed rest and is also used to treat existing blood clots that are blocking blood vessels. Moreover, Rovi Pharmaceuticals Hibor (Bemiparin) is used to prevent harmful blood clots.

Frequently Asked Questions

Savaysa (Edoxaban), Innohep (Tinzaparin), Fraxiparine (Nadroparin) are the few FDA approved Factor Xa Inhibitor.

Total revenues of Daiichi Sankyo’s Andexxa (Coagulation Factor Xa) for the second quarter of FY2019 were $28.4 million.

Major market players include Daiichi Sankyo, Leo Pharma, Aspen Pharma, etc. are few leading market players.

Major Indications for Factor Xa Inhibitor are used to treat cardiovascular diseases, reperfusion injury, acute coronary syndrome, kidney diseases, etc.

There are a total of 10 molecules that are in the Phase-1, Phase-2, and Phase-3 clinical development.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Daiichi Sankyo
  • Leo Pharma
  • Aspen Pharma
  • Rovi Pharmaceuticals Laboratories
  • Astellas
  • AstraZeneca
  • Norgine, Covis Pharma
  • Novartis
  • Sanofi
  • Techdow
  • Pharmadiall
  • Merck (Msd)
  • Chong Kun Dang
  • GC Biopharma
  • CSPC Pharma

Adjacent Markets